Spots Global Cancer Trial Database for ds stage i plasma cell myeloma
Every month we try and update this database with for ds stage i plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01936090 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01842308 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Autologous Bone... Autologous Hema... Carfilzomib Laboratory Biom... Melphalan | 18 Years - | Mayo Clinic | |
| Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant | NCT00839956 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... | Bortezomib Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | NCT00445692 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Clarithromycin Dexamethasone Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01605032 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Busulfan Melphalan Bortezomib Autologous Hema... Peripheral Bloo... | 18 Years - 72 Years | Albert Einstein College of Medicine | |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | NCT01330173 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Vismodegib Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01936090 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | NCT00445692 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Clarithromycin Dexamethasone Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
